8月27日 - ** 医疗保健科技公司Health Catalyst HCAT.O股价盘前下跌3.7%，报3.37美元
** Piper Sandler将股票评级从 "增持 "下调至 "中性"。
** 将目标价从 8 美元下调至 4 美元，意味着该股较上次收盘价溢价 14.3
** 派博指出，该公司缺乏能够表明收入增长复苏和创造股东价值的有机增长动力
** 指出，25财年收入 "指导性下调将所有有机增长从展望中剔除，HCAT现在预计26财年收入将同比下降"。
** HCAT 将其 2025 财年收入展望从之前预测的 3.35 亿美元下调至 3.1 亿美元。
** 12位分析师的平均评级为 "持有"，PT中值为5美元--数据由LSEG编制
** 截至上一交易日收盘，HCAT累计下跌近51
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.